Cat. No.: SCELL-33132

Human wild-type AU565 cell line

Description Human wild-type AU565 cell line is edited by our special CRISPR/Cas9 technology. AU565 is a human breast cancer cell line that can be used to study the differentiation of breast cancer cells. This cell line overexpresses the HER2/neu gene and its receptor
Size 1 vial (2*106 cells/vial)
Parental Cell Line AU565
Biosafety Level 1
Fromat Frozen
Culture Conditions Cells are adherent cells that are cultured at 37°C in a humidified atmosphere with 5% CO2.
Subculture Conditions Subculture at 50-60% confluency. Subculture at 1:6 using 0.25% trypsin and/or trypsin/EDTA. Culture at 5% CO2; 37℃
Freezing Medium Complete culture medium supplemented with 5% (v/v) DMSO
Subculture Guidelines All seeding densities should be based on cell counts obtained by established methods.
The recommended seeding density is 2*104 cells/cm2.
If necessary, a partial replacement of the medium 24 hours before subculture may help promote growth.
When the cells achieve 80-90% confluence, they should be passaged.
Knockout Validation Sanger Sequencing, Western Blot (WB)
Viability >95% viability before freezing.
Adherent /Suspension Adherent
Disease Adenocarcinoma
Purity Immunogen affinity purified
Storage Vapor phase of liquid nitrogen
Sterility Bacteria: Negative
Yeast: Negative
Mycoplasma: Negative
Applications For research use only
Shipping Info Dry Ice
Species Human
Tested Applications Suitable for: ICC, WB, Sanger Sequencing
Tissue Mammary gland/breast
Recommended Control Human wild-type AU565 cell line
Morphology Epithelial cell
Progesterone Receptors Yes
Pathogens HIV: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Product Type Knockout Stable Cell Line
Price Inquiry
About Us

Creative Bioarray is the world leading biological company whose mission focuses on the acquisition, authentication, production, and development of standard reference microbial strains, and cell lines.

Contact Us
  • (USA)
  • (Europe)
Address
  • USA
  • Germany
Copyright © Creative Bioarray. All rights reserved.